Faron Pharmaceuticals Oy (HEL:FARON)

Market Cap	225.50M -6.5%
Revenue (ttm)	n/a
Net Income	-30.95M
EPS	-0.29
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	87,361
Average Volume	342,815
Open	1.948
Previous Close	1.942
Day's Range	1.900 - 1.948
52-Week Range	1.812 - 3.345
Beta	1.27
RSI	43.02
Earnings Date	Mar 4, 2026

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 32
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: FARON